§ Federal grant opportunity · HT942526OCRPCTA

    DoW Ovarian Cancer, Clinical Trial Award

    Christopher Meinberg Grantor is accepting applications for DoW Ovarian Cancer, Clinical Trial Award. The deadline is October 1, 2026 and the published award range is Award amount not published.

    Key facts

    Funder
    Christopher Meinberg Grantor
    Application deadline
    October 1, 2026
    Award range
    Award amount not published
    Eligibility
    Eligibility criteria are published in the funding opportunity announcement.
    Geography
    United States
    Focus areas
    Research
    Opportunity number
    HT942526OCRPCTA

    Program overview

    Summary: The OCRP Clinical Trial Award supports the rapid implementation of clinical trials with the potential to have a significant impact on the treatment or management of ovarian cancer. Distinctive Features: Clinical trials may be designed to evaluate promising new products, pharmacologic agents (drugs or biologics), devices, clinical guidance and/or emerging approaches and technologies. Proposed projects may range from small proof-of-concept trials (e.g., pilot, first-in-human, phase 0) to demonstrate the feasibility or inform the design of more advanced trials through large-scale trials to determine efficacy in relevant patient populations.

    How to apply

    1. Confirm your organization meets the eligibility criteria above.
    2. Read the full funding opportunity announcement from Christopher Meinberg Grantor.
    3. Draft your narrative against the funder's stated priorities and review criteria.
    4. Submit before October 1, 2026, allowing time for registration and validation.

    View the official funding announcement

    Find every grant your organization qualifies for

    Mavenly scores this opportunity against your mission, geography, and funding history — then drafts the proposal with you and tracks the deadline through submission and reporting.